OTUD6B (F6K7V) Rabbit mAb #90190

Storage

Background

Protein ubiquitination and deubiquitination are reversible processes catalyzed by ubiquitinating enzymes (UBEs) and deubiquitinating enzymes (DUBs) (1,2). DUBs are categorized into 5 subfamilies: USP, UCH, OTU, MJD, and JAMM (1,2). The OTU subfamily comprises a group of approximately 100 putative cysteine proteases that are homologous to the ovarian tumor gene product of Drosophila (3). OTU domain-containing protein 6B (OTUD6B) is a member of the OTU family that has active deubiquitinase activity and plays a role in various biological processes (4,5). OTUD6B has been shown to regulate protein synthesis operating downstream of mTORC1 through its two major splicing isoforms, OTUD6B-1 and OTUD6B-2, which target different substrates (6). The switch from OTUD6B-1 to OTUD6B-2 expression may promote protein synthesis and cell proliferation in non-small cell lung cancer (NSCLC) cells (6). OTUD6B is generally upregulated in other types of cancer and is associated with poor prognosis, suggesting that it behaves as an oncogene (7). Alternatively, OTUD6B has been reported to act as a tumor suppressor in hepatocellular carcinoma (HCC) via deubiquitination of VHL and repression of HIF-1α (8). OTUD6B positively regulates type I interferon (IFN) immune response by deubiquitinating and stabilizing the transcription factor IRF3 at Lys315, and overexpression of OTUD6B in mice enhances IFN response following viral infection (9). Additionally, biallelic loss-of-function mutations in the OTUD6B gene have been shown to cause an intellectual disability syndrome that is characterized by cognitive dysfunction and seizures (10).